{
    "clinical_study": {
        "@rank": "110776", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective observational study will evaluate the safety and efficacy of first-line\n      MabThera/Rituxan (rituximab) maintenance therapy in patients with follicular non-Hodgkin's\n      lymphoma. Patients initiated on MabThera/Rituxan maintenance therapy according to the\n      standard of care and in line with the current summary of product characteristics will be\n      followed for a maximum of two years or until disease progression occurs."
        }, 
        "brief_title": "An Observational Study of First-Line Maintenance MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Hodgkin's Lymphoma, Lymphoma, Follicular", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients (according to local regulation)\n\n          -  Patients receiving first-line MabThera/Rituxan maintenance treatment for follicular\n             non-Hodgkin's lymphoma according to the local label and who give consent to take part\n             within 4 weeks after commencing treatment\n\n        Exclusion Criteria:\n\n          -  Contraindications according to the Summary of Product Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with follicular non-Hodgkin's lymphoma receiving first-line Rituximab maintenance\n        treatment"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684865", 
            "org_study_id": "ML27993"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Skopje", 
                    "country": "Macedonia, The Former Yugoslav Republic of", 
                    "zip": "1000"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Macedonia, The Former Yugoslav Republic of"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML27993 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Macedonia:  Ministry of Health Pharmaceuticals Bureau"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684865"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Event free rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}